Eflornithine is Safer Than Melarsoprol for the Treatment of Second-Stage Trypanosoma Brucei Gambiense Human African Trypanosomiasis.

Hdl Handle:
http://hdl.handle.net/10144/17284
Title:
Eflornithine is Safer Than Melarsoprol for the Treatment of Second-Stage Trypanosoma Brucei Gambiense Human African Trypanosomiasis.
Authors:
Chappuis, F; Udayraj, N; Stietenroth, K; Meussen, A; Bovier, P A
Journal:
Clinical Infectious Diseases
Abstract:
Patients with second-stage human African trypanosomiasis treated with eflornithine (n = 251) in 2003 in Kiri, southern Sudan, had an adjusted relative risk of death of 0.2 and experienced significantly fewer cutaneous and neurological adverse effects than did patients who were treated with melarsoprol in 2001 and 2002 (n = 708).
Affiliation:
Médecins Sans Frontières, Geneva University Hospitals, Geneva, Switzerland. francois.chappuis@hcuge.ch
Publisher:
Published by: Infectious Diseases Society of America
Issue Date:
1-Sep-2005
URI:
http://hdl.handle.net/10144/17284
DOI:
10.1086/432576
PubMed ID:
16080099
Additional Links:
http://www.journals.uchicago.edu/page/cid/brief.html
Language:
en
ISSN:
1537-6591
Appears in Collections:
Trypanosomiasis/Sleeping Sickness

Full metadata record

DC FieldValue Language
dc.contributor.authorChappuis, F-
dc.contributor.authorUdayraj, N-
dc.contributor.authorStietenroth, K-
dc.contributor.authorMeussen, A-
dc.contributor.authorBovier, P A-
dc.date.accessioned2008-01-31T16:21:00Z-
dc.date.available2008-01-31T16:21:00Z-
dc.date.issued2005-09-01-
dc.identifier.citationEflornithine is Safer Than Melarsoprol for the Treatment of Second-Stage Trypanosoma Brucei Gambiense Human African Trypanosomiasis. 2005, 41 (5):748-51 Clin. Infect. Dis.en
dc.identifier.issn1537-6591-
dc.identifier.pmid16080099-
dc.identifier.doi10.1086/432576-
dc.identifier.urihttp://hdl.handle.net/10144/17284-
dc.description.abstractPatients with second-stage human African trypanosomiasis treated with eflornithine (n = 251) in 2003 in Kiri, southern Sudan, had an adjusted relative risk of death of 0.2 and experienced significantly fewer cutaneous and neurological adverse effects than did patients who were treated with melarsoprol in 2001 and 2002 (n = 708).en
dc.language.isoenen
dc.publisherPublished by: Infectious Diseases Society of America-
dc.relation.urlhttp://www.journals.uchicago.edu/page/cid/brief.html-
dc.rightsArchived on this site with permission and copyright by the Infectious Diseases Society of Americaen
dc.subject.meshAdolescenten
dc.subject.meshAdulten
dc.subject.meshChilden
dc.subject.meshEflornithineen
dc.subject.meshFemaleen
dc.subject.meshHumansen
dc.subject.meshMaleen
dc.subject.meshMelarsoprolen
dc.subject.meshSudanen
dc.subject.meshTrypanocidal Agentsen
dc.subject.meshTrypanosomiasis, Africanen
dc.titleEflornithine is Safer Than Melarsoprol for the Treatment of Second-Stage Trypanosoma Brucei Gambiense Human African Trypanosomiasis.en
dc.contributor.departmentMédecins Sans Frontières, Geneva University Hospitals, Geneva, Switzerland. francois.chappuis@hcuge.chen
dc.identifier.journalClinical Infectious Diseasesen

Related articles on PubMed

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.